BridgeBio Pharma Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for BridgeBio Pharma, Inc. (BBIO) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Operating Activities
Net Income-535.76-653.25-484.65-586.45-505.49-288.59
Depreciation & Amortization6.086.496.775.841.460.00
Stock Based Compensation95.80108.7191.5699.5158.460.00
Change in Working Capital32.045.0628.080.761.24-33.62
Change in Accounts Receivable-2.9715.3315.17-19.750.000.00
Change in Accounts Payable1.512.78-0.352.83-0.740.00
Change in Other Working Capital17.1222.34-88.4518.5015.670.00
Other Operating Activities17.1222.34-88.45101.0694.4938.48
Net Cash from Operating Activities-520.73-527.72-419.49-497.93-399.71-253.59
Investing Activities
Capital Expenditures-8.91-1.31-6.3248.257.522.64
Acquisitions-0.14-0.50-55.56-53.380.00-2.50
Purchases of Investments-114.08-137.26-193.06-643.28-38.720.00
Sales/Maturities of Investments158.23193.11532.52-99.20-45.48-212.12
Other Investing Activities25.68-0.50110.0076.35-6.760.78
Net Cash from Investing Activities60.7854.03453.15-200.83-52.99-217.25
Financing Activities
Debt Repayment-473.420.00-20.49-140.18-13.040.18
Common Stock Issued314.74449.814.853.821.21367.16
Common Stock Repurchased-7.53-6.88-1.56-204.75-75.710.00
Dividends Paid0.000.000.000.000.001.00
Other Financing Activities-43.50-0.800.84-147.63-28.90-6.28
Net Cash from Financing Activities748.46451.54-13.13736.45447.19398.79
Summary
Net Change in Cash288.51-22.1520.5237.69-5.52-72.05
Cash at Beginning of Period394.73416.88396.37358.68364.20436.25
Cash at End of Period683.24394.73416.88396.37358.68364.20
Free Cash Flow-529.63-529.03-425.82-546.18-407.23-256.23
Supplemental Disclosures
Interest Paid91.3461.1154.4429.7715.326.09